Oncology (all articles)
Study | Removal of thymus in adults linked to increased death, cancer incidence
4 Aug, 2023 | 12:09h | UTCHealth Consequences of Thymus Removal in Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Doctors have long considered the thymus expendable. But could removing it be fatal? – Science
The thymus withers away after puberty. But it may be important for adults – Science News
Thymus gland critical for adult health, study finds – News Medical
Commentary on Twitter
In a study by Kooshesh et al., mortality, the risk of cancer, and levels of proinflammatory cytokines were higher among adults whose thymus had been removed than among control patients. Read the full study results: https://t.co/poaAiELsKG
— NEJM (@NEJM) August 2, 2023
NICE Updated Guideline | Diagnosis and management of lung cancer
4 Aug, 2023 | 12:05h | UTCLung cancer: diagnosis and management – National Institute for Health and Care Excellence
ASCO Guideline Update | Management of Stage III Non–Small-Cell Lung Cancer
4 Aug, 2023 | 12:03h | UTC
ACP Guidance | Asymptomatic CRC screening advised from age 50 with fecal occult blood test every 2 years or colonoscopy every 10 years
3 Aug, 2023 | 13:48h | UTCNews Release: ACP issues updated guidance for colorectal cancer screening of asymptomatic adults – American College of Physicians
Commentary: Start screening for colorectal cancer at age 50 years, ACP suggests – ACP Internist
Summary for Patients: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults – Annals of Internal Medicine
Systematic Review | Interstitial lung disease incidence at 11.7% in metastatic breast cancer patients using trastuzumab deruxtecan
3 Aug, 2023 | 13:36h | UTC
M-A | Significant QOL and mental health improvements in caregivers via targeted interventions
3 Aug, 2023 | 13:28h | UTC
RCT | No significant recurrence-free survival improvement with everolimus post-renal carcinoma surgery
3 Aug, 2023 | 13:17h | UTCAdjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT | Early oral antibiotic switch in low-risk neutropenic sepsis shows mixed results
3 Aug, 2023 | 13:15h | UTC
Review | Atypical hyperplasia of the breast: Clinical cases and management strategies
3 Aug, 2023 | 13:07h | UTC
RCT | Lazertinib offers 20.6-month of median PFS in EGFR-mutated NSCLC vs 9.7 months with gefitinib
2 Aug, 2023 | 13:55h | UTC
RCT | Camrelizumab-rivoceranib outperforms sorafenib as first-line therapy for unresectable HCC
2 Aug, 2023 | 13:53h | UTCCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Qin et al – Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyhttps://t.co/YoutfY5IkA#LiverTwitter #OncTwitter #LiverCancer #HCC pic.twitter.com/Tcvm6D3kCW
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) July 25, 2023
M-A | High-volume disease, T stage 4 show largest docetaxel benefit in prostate cancer
2 Aug, 2023 | 13:51h | UTCCommentaries:
Disease Volume and T Stage Affect Docetaxel/ADT Efficacy in Prostate Cancer – Cancer Network
Commentary on Twitter
NEW: A systematic review and meta-analysis of individual patient data from the STOPCAP M1 collaboration aims to obtain up-to-date estimates of the effects of docetaxel in patients with metastatic hormone-sensitive prostate cancer. #pcsmhttps://t.co/7mqXeIXMQ5 pic.twitter.com/A7AmjipnVq
— The Lancet Oncology (@TheLancetOncol) July 5, 2023
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma
1 Aug, 2023 | 14:24h | UTCPart 1: Diagnostics and prevention – European Journal of Cancer
Part 2: Treatment – European Journal of Cancer
Nonrandomized Controlled Trial | Long-term survival of 80% in selected colorectal cancer patients post liver transplant
1 Aug, 2023 | 14:20h | UTCLong-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary on Twitter
Selected patients with liver-only CRLM and favorable pre-transplant prognostic scoring have long-term OS comparable to conventional indications for LT, providing a potential curative treatment option in patients otherwise offered only palliative treatments https://t.co/Xso5R7IDsX pic.twitter.com/uwEWijcrBp
— JAMA Surgery (@JAMASurgery) July 26, 2023
RCT | Niraparib after first-line platinum-based chemotherapy extends PFS vs. placebo in newly diagnosed advanced ovarian cancer
31 Jul, 2023 | 13:58h | UTCSee also: Visual Abstract
Commentary: Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer – The ASCO Post
Review | The evolving landscape of salivary gland tumors
27 Jul, 2023 | 12:58h | UTCThe evolving landscape of salivary gland tumors – CA: A Cancer Journal for Clinicians
Perspective | Reconsidering the language of serious illness
26 Jul, 2023 | 13:29h | UTCReconsidering the Language of Serious Illness – JAMA (free for a limited period)
Commentary on Twitter
"When clinicians, from a position of authority, describe patients with respiratory failure as needing intubation, patients and families presume intubation is what should be done."
Reconsidering the Language of Serious Illness https://t.co/IXDtDDPYTw
— Shunichi Nakagawa (@snakagawa_md) July 24, 2023
RCT | Dysphagia-optimized intensity-modulated radiotherapy better preserves swallowing function in pharyngeal cancer patients
25 Jul, 2023 | 13:52h | UTCCommentaries:
Radiation approach improves swallowing in head, neck cancer – MDedge
Commentary on Twitter
NOW OF: The (DARS) phase 3 RCT investigates if dysphagia-optimised intensity-modulated radiotherapy (IMRT) reduces radiation dose to the dysphagia and aspiration related structures and improves swallowing function compared with standard IMRT.#hncsmhttps://t.co/CzpxsNxx1N pic.twitter.com/xNgfm43tHE
— The Lancet Oncology (@TheLancetOncol) July 7, 2023
Phase 2 Trial | The addition of immunotherapy to stereotactic ablative radiotherapy may enhance EFS in early-stage NSCLC
25 Jul, 2023 | 13:36h | UTCStereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Systematic Review | Post-mastectomy RT likely lowers recurrence and improves survival in early breast cancer with 1-3 positive nodes
25 Jul, 2023 | 13:34h | UTC
Review | Radiomics-based fertility-sparing treatment in endometrial carcinoma
24 Jul, 2023 | 13:00h | UTC
RCT | Combined pre-operative olanzapine regimen lowers postoperative nausea in high-risk cancer patients
24 Jul, 2023 | 12:49h | UTC
Phase 2 Trial | Nivolumab shows promise as adjuvant therapy in completely resected Merkel cell carcinoma
20 Jul, 2023 | 11:02h | UTCAdjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Systematic Review | Platinum doublet therapy outperforms non-platinum for advanced NSCLC, performance status 2 patients
20 Jul, 2023 | 10:56h | UTC
ASCO Guideline | Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy
19 Jul, 2023 | 14:31h | UTC